-
Daqing Oilfield harvests billion-ton-level shale oilfield to produce 1 million tons in 2022
Time of Update: 2021-09-13
According to the 21st Century Business Herald reporter, Daqing Oilfield is taking Gulong shale oil as an important strategic area, fully implementing the new development concept, and speeding up various tasks .
-
Can the new medical insurance catalog still produce 1 billion yuan "magic medicine"?
Time of Update: 2017-03-08
Source: Medical Economic News March 8, 2017 the Ministry of human resources and social security released the 2017 medical insurance drug catalog on February 23 For the new catalog, there are different
-
Nat Biotech: Producing 1 billion CAR-T cells at a time, the new CRISPR technology efficiently
Time of Update: 2022-09-20
In this latest study, the research team developed a new CRISPR system that utilizes a single-stranded DNA (ssDNA) HDR template (HDRT) that binds to the Cas9 target sequence to achieve 2-3 times the knock-in efficiency and yield relative to dsDNA.
-
Zhenhai Refinery's Polybutene-1 Industrial Demonstration Plant Produces Qualified Products
Time of Update: 2022-09-17
progress On February 8, Sinopec's "Ten Dragons" research project, the thousand-ton high-grade polybutene-1 industrial demonstration plant, produced qualified products and achieved stable operation, marking Zhenhai Refinery's major achievements in the field of high-end synthetic new materials.
-
Kingfa Technology: plans to produce up to 1 million tons of recycled plastic in 2030
Time of Update: 2022-08-27
In the first quarter of 2021, the sales volume of fully biodegradable plastics was 26,700 tons, and the sales volume of special engineering plastics was 4,400 tons According to the quarterly report, modified plastic products include original modified plastics and environmentally friendly high-performance recycled plastics.
-
Zhang Yuzhuo, chairman of Sinopec: masks should be produced quickly and the production target should be 1 million pieces per day
Time of Update: 2022-08-22
. According to Xinhua News Agency, during the Spring Festival, Xinlong Holdings' production of meltblown non-woven fabrics for bacterial filtration of masks operates 24 hours a day to ensure the supply of raw materials to downstream mask manufacturers .
-
The 12th anniversary of Zhenhai Refinery's 12th anniversary of the high-efficiency operation of No. 1 ethylene produced 12.85 million tons of ethylene
Time of Update: 2022-05-22
Over the past 12 years, Zhenhai Refinery has given full play to the advantages of raw materials, regional advantages, and refining and chemical integration, benchmarking against the world's first-class standards, aiming at "resource recycling, energy efficiency, and emission minimization", tap potential, work hard, and continue to advance The important economic and technical indicators of No.
-
Qilu's first over 100 million antihypertensive drug appraised the first domestically produced $1 billion variety
Time of Update: 2022-04-17
Recently, Qilu Pharmaceutical has made new progress in the field of hypertension medication: carvedilol tablets have been successfully reviewed, the first in China, and the sales of this product in China's public medical institutions will exceed 100 million yuan in 2020; Riociguat tablets reported It is the first domestically produced drug, and currently no generic drugs have been approved in China .
-
Zhenhai Refinery's Polybutene-1 Industrial Demonstration Plant Produces Qualified Products
Time of Update: 2022-03-07
On February 8, Sinopec's "Ten-train" research project, the thousand-ton high-grade polybutene-1 industrial demonstration plant, produced qualified products and achieved stable operation, marking that Zhenhai Refinery has made great achievements in the field of high-end synthetic new materials.
-
of domestically produced Class 1 innovative drugs, and the number of traditional Chinese medicine applications reaches a new high!
Time of Update: 2022-01-24
Figure 9 Distribution of declarations by province in 2021 Data source: Yaozhi Data, Yaozhi Consulting Let us analyze in detail the registration acceptance and review of chemical drugs, traditional Chinese medicines, biological products, priority review and breakthrough therapy .
-
Reactions that may produce hazardous products (by-products) (1)
Time of Update: 2022-01-19
1. Reactions that may produce explosive products (by-products)example 1 Application process: Dissolve reaction substrate A (150.
Example 2 Application process: Add dimethyl sulfoxide (6.
After the addition was completed, the reaction solution was stirred at 30°C for 10 min .
-
[Heavyweight] The first domestically produced Class 1 new anti-ED drug, AIRIS®, is on the market
Time of Update: 2022-01-09
New product launches and multi-channel simultaneous efforts As a domestic patented new anti-ED drug, AIRIS® Aldenafil Citrate Tablets has the advantages of good patient experience, high safety, and low side effects compared with similar products on the market .
-
The first domestically produced PD-(L)1 monoclonal antibody head-to-head Phase 3 clinical trial!
Time of Update: 2021-12-26
Today, Chia Tai Tianqing Pharmaceutical Group announced the launch of an "evaluation of TQB2450 injection combined with platinum-containing chemotherapy followed by sequential TQB2450 injection combined with anlotinib hydrochloride capsules versus tislelizumab injection combined with platinum-containing chemotherapy as the first-line treatment A randomized, open-label, parallel-controlled, multi-center phase III clinical trial on the effectiveness and safety of advanced non-squamous non-small cell lung cancer" .
-
Since November, a number of domestically produced Class 1 new drugs have been applied for clinical application and marketing
Time of Update: 2021-12-08
Prior to this, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng has also received CDE approval for the marketing application of Brainshang Lesheng Granules submitted by the new drug category 1.
-
Last week, 2 domestically produced Class 1 new drugs were approved for listing at the same time
Time of Update: 2021-12-01
Subcutaneous injection of PD-L1 antibody was approved for marketing in China On November 25, the National Medical Products Administration (NMPA) conditionally approved the listing of PD-L1 single domain antibody Envida® (Envolimab injection) .
